Key result
Hepatitis B virus carrier status was associated with higher and prolonged cardiac troponin I levels 24 hours after a 100-km ultramarathon (β=0.03, p=0.08).
Why the study?
Does hepatitis B carrier status affect cardiac troponin I levels and kinetics after a 100-km ultramarathon?
Observational (n=26)
Does hepatitis B carrier status affect cardiac troponin I levels and kinetics after a 100-km ultramarathon?
Hepatitis B carrier status may be associated with higher and more prolonged elevations of cardiac troponin I following extreme endurance exercise.
May caution troponin interpretation in HBV carriers after ultramarathons; hypothesis-generating and should not yet change practice.
BACKGROUND: Prolonged endurance exercise is known to cause elevation of cardiac troponin I (cTnI). Previous studies have reported the correlation of several factors with exercise-induced cTnI release. However, the investigation of the predictors for elevated cTnI and postrace kinetics of cTnI after ultramarathon running is lacking, especially in an Oriental population. METHODS: Twenty-six participants, including eight hepatitis B virus carrier (HBVc) runners, who finished a 100-km ultramarathon in Taiwan were enrolled. For each participant, blood samples were collected 1 week before the race, as well as immediately and 24 hours after the finish. RESULTS: The results showed that 19 runners (73.1%) had postrace elevated cTnI levels and eight (30.8%) had elevated cTnI values lasting more than 24 hours after the run. A multiple linear regression analysis demonstrated that the HBV status was a factor related to the high level of cTnI after 24 hours of running (β=0.03, p=0.08). The recovery of plasma cTnI levels was delayed in ultramarathon runners with latent HBV infection. Among HBVc runners, multiple linear regression analyses showed age (β=-0.01), previous running experience (β=-0.06), training distance (β=0.37), and 4 hours of running distance (β=-0.04) as significant predictors of higher postrace cTnI levels. CONCLUSION: For most athletes, cTnI values significantly increased immediately following the race in the absence of adverse clinical sequelae, and HBVc runners had higher and prolonged cTnI levels. While several factors are identified for such HBV effects, the specific causes need further elucidation.
No takes yet. Share an insight, caveat, or question.
Li et al. (2017) conducted an observational in 100-km ultramarathon runners (n=26). Hepatitis B virus carrier status vs. Non-HBV carrier status was evaluated on High level of cTnI after 24 hours of running (β=0.03, p=0.08). Hepatitis B virus carrier status was associated with higher and prolonged cardiac troponin I levels 24 hours after a 100-km ultramarathon (β=0.03, p=0.08).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: